**Author details**

*New Insights into Metabolic Syndrome*

incidence and cancer mortality.

*Effects of aspirin on cancer incidence and cancer mortality.*

cancer and cancer-associated VTE.

The author declares no conflict of interest.

**11. Conclusion**

**Table 3.**

**Conflict of interest**

regular aspirin use does not decrease cancer incidence or cancer mortality [57–59] (**Table 3**). Further studies are needed to confirm the effects of aspirin on cancer

HR: Hazard ratio (aspirin vs placebo or no-aspirin).

Outcome HR Reference Incidnce of colon cancer 0.76(0.60 – 0.96) [53] Death due to colon cancer 0.65(0.48 – 0.88) [53] Death due to cancer 0.79(0.68 – 0.92) [54] Cancer with disant metastasis 0.64(0.48 – 0.84) [55]

Representative reports of large-scale meta-analysis

Outcome HR Reference Incidence of cacer 1.24(1.06 –1.46) [57] Death due to cancer 1.08(0.85 –1.38) [57] Death due to cancer 1.31(1.10 –1.56) [58] Incidence of cacer 1.01(0.92 –1.11) [59]

Recent publications

Various factors are involved in carcinogenesis and occurrence of cancer-associated VTE. Certain diets and nutrition may reduce the risk of VTE. Some lifestyles may reduce cancer incidence, and other lifestyles increase the risk of cancer. Further studies are needed to create ideal diet, nutrition, and lifestyle to reduce the risk of

**130**

Kenji Yokoyama Department of Hematology/Oncology, Tokai University Hachioji, Hachioji, Japan

\*Address all correspondence to: yk092750@tsc.u-tokai.ac.jp

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
